HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

Abstract
This open, randomised clinical study, conducted from June 1988 to December 1989, included 84 patients with clinical and radiological findings of atypical pneumonia. All patients were treated with a total dose of 1.5 g azithromycin, a new azalide antibiotic. In Group I, azithromycin was administered for three days (500 mg once daily). In Group II, azithromycin was administered for five days (250 mg b.i.d. on day 1, followed by 250 mg once daily on days 2 to 5). Causative pathogens were identified by serological methods. Of the 41 patients in Group I, Mycoplasma pneumoniae, Chlamydia psittaci and Coxiella burnetti were identified in 19, 4 and 3 patients, respectively. In Group II there were 43 patients; Mycoplasma pneumoniae was identified in 24, Chlamydia psittaci in 4 and Coxiella burnetti in 3. Only patients with known causative pathogens were included in the evaluation of clinical efficacy. All patients were clinically cured by day 5; most of the patients became afebrile within 48 h of starting treatment. Side effects were observed in one patient in Group I and in one patient in Group II. The results suggest that a 1.5 g total dose of azithromycin is equally effective when administered as a three- or five-day regimen for the treatment of atypical pneumonia.
AuthorsS Schönwald, V Skerk, I Petricevic, V Car, L Majerus-Misic, M Gunjaca
JournalEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 10 Issue 10 Pg. 877-80 (Oct 1991) ISSN: 0934-9723 [Print] Germany
PMID1662637 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Erythromycin
  • Azithromycin
Topics
  • Adult
  • Azithromycin
  • Chlamydia Infections (drug therapy)
  • Drug Administration Schedule
  • Erythromycin (administration & dosage, analogs & derivatives, metabolism, therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phagocytes (metabolism)
  • Pneumonia (drug therapy)
  • Pneumonia, Mycoplasma (drug therapy)
  • Q Fever (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: